ArticleNPJ breast cancer2025

MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.

Ayako Nakashoji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.